Comparisons between retatrutide, tirzepatide, and semaglutide show up constantly online, usually with a simple ranking: triple beats dual beats single. The published trial data is more nuanced than that headline. Each compound activates a different set of incretin-related receptors, ran in separate trials with different durations and populations, and only two of the three are approved medicines.
Everything below summarizes published clinical trial data for investigational and approved pharmacologic agents. Research-grade peptide materials sold for laboratory use are not substitutes for approved drugs and are intended strictly for in-vitro and laboratory research, not for human or animal consumption.
Three Compounds, Three Receptor Profiles
The simplest way to organize the comparison is by receptor activity:
- Semaglutide: GLP-1 receptor agonist (single pathway)
- Tirzepatide: GLP-1 and GIP receptor agonist (dual pathway)
- Retatrutide: GLP-1, GIP, and glucagon receptor agonist (triple pathway)
Adding receptors does not automatically mean "better" in every outcome. Each additional pathway changes appetite signaling, glucose handling, and (in retatrutide's case) energy expenditure through glucagon receptor activity. For background on retatrutide's third pathway, see our overview of how retatrutide's appetite mechanisms differ from dual agonists and the plain-English explainer on triple-agonist research.
What the Landmark Trials Reported
These figures come from separate randomized trials, not a head-to-head study. Comparing them side by side is useful for context, but it is not a direct efficacy ranking.
| Compound | Key trial | Approx. mean weight change | Duration | Regulatory status |
|---|---|---|---|---|
| Semaglutide 2.4 mg | STEP 1 (Wilding et al., NEJM 2021) | −14.9% vs −2.4% placebo | 68 weeks | FDA-approved (obesity indication) |
| Tirzepatide 15 mg | SURMOUNT-1 (Jastreboff et al., NEJM 2022) | −20.9% vs −3.1% placebo | 72 weeks | FDA-approved (obesity indication) |
| Retatrutide 12 mg | Phase 2 (Jastreboff et al., NEJM 2023) | −24.2% vs −2.1% placebo | 48 weeks | Investigational (Phase 3 ongoing) |
A few details that often get lost in summary tables:
- Retatrutide's 48-week data showed dose-dependent responses across 1 mg, 4 mg, 8 mg, and 12 mg arms, the 24.2% figure is the 12 mg group's mean at week 48, not a guarantee at every dose.
- Tirzepatide's trial ran four weeks longer than retatrutide's Phase 2 and enrolled a much larger population (SURMOUNT-1, n≈2,539).
- Semaglutide's STEP 1 trial established the single-agonist benchmark that later dual- and triple-agonist trials are compared against.
Tolerability: What the Trials Describe
Across all three classes, gastrointestinal adverse events dominate the tolerability profile, nausea, diarrhea, and constipation, mostly during dose escalation. Retatrutide's Phase 2 paper reported GI events in 73-94% of treated participants depending on dose arm, versus 70% placebo, with discontinuation due to adverse events ranging from 6% to 16% across retatrutide arms versus 0% placebo.
Tirzepatide's SURMOUNT-1 trial reported treatment discontinuation due to adverse events in 4.3%, 7.1%, 6.2%, and 2.6% of participants at 5 mg, 10 mg, 15 mg, and placebo, respectively. Semaglutide's STEP 1 trial reported discontinuation due to GI events in 4.5% of the semaglutide group versus 0.8% placebo.
Cross-trial tolerability comparisons are even harder than efficacy comparisons because dose-escalation schedules, starting doses, and population characteristics differ. For a deeper retatrutide-specific safety breakdown, see retatrutide Phase 2 safety data.
Why "Which Works Best?" Is the Wrong Research Question
In laboratory and literature review contexts, the more useful questions are mechanistic:
- How does adding GIP co-agonism change GI tolerability compared with GLP-1 mono-agonism?
- What does glucagon receptor activity contribute to energy expenditure in preclinical and early clinical models?
- How do receptor occupancy and half-life differ between molecules with similar endpoints?
Retatrutide remains investigational. Tirzepatide and semaglutide are approved for specific regulated indications with defined prescribing frameworks. Published research about any of these compounds does not make a research-grade catalog version an approved medicine.
For endocrine and metabolic pathway context beyond weight endpoints, our write-up on tirzepatide and PCOS-related research covers a different but related area of published investigation.
Handling Research-Grade Materials in the Lab
Labs studying these peptides in controlled models need consistent reconstitution technique, documented batch identity, and proper cold-chain handling. Practical references on the site include the peptide storage and reconstitution guide, how to read a COA, and the COA lookup tool. Retatrutide, tirzepatide, and related catalog materials are listed under research compliance as RUO-only products.
Common Questions
Has a three-way head-to-head trial been run? Not as of the published literature reviewed here. Existing comparisons rely on separate trials with different designs.
Does higher weight loss in trials mean a research peptide is "stronger"? Trial percentages describe investigational or approved drug performance in specific populations, not potency rankings of catalog materials.
Is retatrutide FDA-approved? No. It remains in Phase 3 development as of the trials cited above.
Where can I find retatrutide for laboratory research? See the retatrutide product page and verify batch documentation via COA lookup.
References
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. Read the study
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. Read the study
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. Read the study
- ClinicalTrials.gov. Retatrutide Phase 2 registration (NCT04881760). View registration
